Sign up to save your podcasts
Or
Share Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH
In this week's podcast, we'll learn about targeting mutant calreticulin in MPNs, or myeloproliferative neoplasms. Then, it’s time to address bleeding and clotting in cancer. Results of the prospective, observational CAT-BLED study provide much needed data on the high risk of clinically relevant bleeding, and its association with all-cause mortality, among cancer patients receiving systemic therapy. Finally, we'll revisit diagnostic guidelines for familial HLH, or hemophagocytic lymphohistiocytosis. The authors present new and improved diagnostic criteria with revised clinical criteria, and guidelines on cellular and genetic diagnostic assays.
Featured Articles:
- Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN
- Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study
- Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited
View all episodes
By American Society of Hematology
4.1
4848 ratings
In this week's podcast, we'll learn about targeting mutant calreticulin in MPNs, or myeloproliferative neoplasms. Then, it’s time to address bleeding and clotting in cancer. Results of the prospective, observational CAT-BLED study provide much needed data on the high risk of clinically relevant bleeding, and its association with all-cause mortality, among cancer patients receiving systemic therapy. Finally, we'll revisit diagnostic guidelines for familial HLH, or hemophagocytic lymphohistiocytosis. The authors present new and improved diagnostic criteria with revised clinical criteria, and guidelines on cellular and genetic diagnostic assays.
Featured Articles:
- Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN
- Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study
- Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited
More shows like Blood Podcast
View all
JAMA Editors' Summary
129 Listeners
Hematologic Oncology Update
71 Listeners
NEJM This Week
319 Listeners
The Hematologist
26 Listeners
JAMA Clinical Reviews
489 Listeners
Mayo Clinic Talks
273 Listeners
VJHemOnc Podcast
2 Listeners
Annals On Call Podcast
186 Listeners
The Curious Clinicians
362 Listeners
The BSH Guidelines Official Podcast
3 Listeners
EHA Unplugged
2 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
165 Listeners
Blood Cancer Talks
48 Listeners
HemeTalks: Conversations in Hematology Education
1 Listeners